Develops therapies for neurological and psychiatric disorders, focusing on innovative drug delivery platforms.
NLS Pharmaceutics AG is a pioneering biopharmaceutical firm dedicated to advancing therapies for rare and intricate central nervous system disorders. Based in Zurich, Switzerland, the company specializes in the discovery and development of treatments targeting conditions such as narcolepsy, idiopathic hypersomnia, and other uncommon sleep disorders. Additionally, NLS Pharmaceutics AG focuses on neurodevelopmental disorders, including attention deficit hyperactivity disorder (ADHD), underscoring its commitment to addressing significant unmet medical needs within the field.
At the forefront of its innovative pipeline are lead product candidates like Quilience, designed to alleviate excessive daytime sleepiness and cataplexy associated with narcolepsy. Another promising candidate, Nolazol, is aimed at treating ADHD, reflecting the company's broad therapeutic approach and potential impact across diverse neurological conditions.
Founded in 2015, NLS Pharmaceutics AG continues to expand its capabilities in biopharmaceutical research and development. With a strong emphasis on scientific innovation and clinical advancement, the company is poised to make significant strides in improving outcomes for patients affected by complex CNS disorders globally.